Page 38 - Compass Pathways News Today

Article content Let’s take a look at how investors can add exposure to the psychedelics sector and add into their portfolio without having to purchase multiple companies and actively manage their portfolio. Invest in a Psychedelics ETF Exchange-traded funds, or ETFs, are one of the easiest ways for investors to build exposure to different corners of the market into their portfolios. They provide instant diversification to a particular theme with exposure to many different stocks in a single s...

Article content Let’s take a look at how investors can add exposure to the psychedelics sector and add into their portfolio without having to purchase multiple companies and actively manage their portfolio. Invest in a Psychedelics ETF Exchange-traded funds, or ETFs, are one of the easiest ways for investors to build exposure to different corners of the market into their portfolios. They provide instant diversification to a particular theme with exposure to many different stocks in a single s...

Save Share It’s a strange portfolio for these strange financial times: space travel, psychedelics, movies, COVID-19, crypto, life extension, weed and SPACs. Those are just some of Christian Angermayer’s investments. On Wall Street the name rings few bells. Yet for better or worse, the 42-year-old German billionaire looks like a symbol of the age, or at least the past 12 crazy months. He’s made a fortune on the risky and faddish during the great bull market in everything. His fami...

ZeroHedge - On a long enough timeline, the survival rate for everyone drops to zero

What Did the Stock Market Do Today? 3 Big Stories to Catch Up On. InvestorPlace 1 min ago Sarah Smith © Source: Shutterstock Street sign for Wall Street pictured in front of several American flags representing american stocks Monday trading may be over, but make sure you are all caught up and ready for the week. To start, what did the stock market do today? And what else should be on your radar? © Provided by InvestorPlace Street sign for Wall Street pictured in front of...

The U.S. House of Representatives Voted for the Secure and Fair Enforcement Banking Act for the Fourth time, but the Bill Aimed at Enabling Banks to Provide its Services to State-Legal Cannabis Businesses Never Before Passed to the Senate Floor Cantor Fitzgerald’s analyst Pablo Zuanic doesn’t see the bill reaching a Senate vote either, as leading Democrats there are pushing for broader reform, and not for “isolated federal level changes” for the industry. Back in March, Senate Majority ...

Psychedelics Company MindMed Trips In Nasdaq Debut Share to Linkedin JR Rahn is the cofounder and co-CEO of MindMed, a psychedelic drug development company based in New York. Courtesy MindMed Psychedelic drug development startup MindMed became the second company of its kind to list on the Nasdaq on Tuesday, but its share price cashed 30% during the first day of trading.   The company, which went public on Canada’s NEO stock exchange through a reverse takeover in March 2020 and has a current...

Can magic mushrooms really help you understand bitcoin? That’s what one German billionaire says. But it’s not why the Aztecs and the hippies were such fans A potential cure for depression? Cultivated magic mushrooms. Photograph: Nigel Dodds/Alamy A potential cure for depression? Cultivated magic mushrooms. Photograph: Nigel Dodds/Alamy Mon 26 Apr 2021 11.23 EDT Last modified on Mon 26 Apr 2021 12.59 EDT Name: The shroom boom. Age: Ancient rock art in Castilla-La Mancha in Spain suggests t...

Months after submitting an application to uplist its shares from Toronto’s NEO exchange, MindMed (OTCQB:MMEDF) confirmed it will commence trading on the Nasdaq Capital Market under the ticker symbol “MNMD” on April 27. MindMed will continue to be listed on the NEO exchange, and its subordinate voting shares will remain listed on the OTCQB until trading on the Nasdaq begins. “We believe this listing will increase our visibility in the marketplace, improve liquidity, broaden and diversif...

(MENAFN - Baystreet.ca) A new study led by the Imperial College Londons Centre for Psychedelic Research has yielded promising results for the use of psilocybin in psychiatric therapy. Psilocybin, the psychoactive compound of magic mushrooms - was pitted up against popular SSRI (selective serotonin reuptake inhibitor) escitalopram. Results were measured through scoring tallied after surveying participants on their sleep, energy, appetite, mood and suicidal ideations. The largely-negatively ...